Dr. Lary A. Robinson, MD

Dr. Robinson, a native of Kansas, received his undergraduate B.A. degree in anthropology at the University of Kansas and his medical degree from the Washington University School of Medicine in St. Louis, Missouri. He completed his internship and residency in general and cardiothoracic surgery at the Duke University Medical Center. Additionally, he completed a fellowship in cardiac research and clinical cardiac surgery at the St. Thomas’ Hospital in London. He also served as a Flight Surgeon at the rank of Major, USAF in Thailand during the Vietnam War. A Diplomat of the American Board of Surgery, the American Board of Thoracic Surgery as well as certified in Surgical Critical Care, Dr. Robinson began his practice at the University of Nebraska Medical Center where he was an Associate Professor of Surgery and Pharmacology and the Clinical Director of the Clinical Perfusion Science Education Program. Dr. Robinson then came to the University of South Florida College of Medicine in Tampa …in 1994 where he is currently a Professor of Surgery (Thoracic) and Interdisciplinary Oncology. He practices thoracic surgical oncology at the Moffitt Cancer Center as a Senior Member with Tenure of the Moffitt Medical Group. He is also Director of the Pancoast Tumor Program in the Department of Thoracic Oncology. He also helped found the Center for Infection Research in Cancer (CIRC) in 2012.  He is also the co-founder and President of Prelude to a Cure, Inc., a non-profit charity dedicated to raising funds to support lung cancer research. Finally, he is the Director of the new Lung Cancer Early Detection Center at Moffitt.Dr. Robinson is the author or co-author of over 160 medical publications. He is directly involved as Principal Investigator in 3 ongoing clinical cancer research protocols involving lung cancer and the microbiome, lung cancer in never-smoking women and the use of biomarkers for diagnosis, risk stratification and long-term surveillance of lung cancer. He is also Principal Investigator for a prospective multi-center clinical study evaluating the influence of the gut microbiome on the effectiveness of immunotherapy for advanced lung cancer. Clinically, he is a member of the multidisciplinary thoracic oncology group involved in the evaluation and treatment of all stages of lung cancer, thymoma, and other thoracic cancers which includes aggressive, combined modality therapy including numerous clinical trials.

Moffitt Cancer Center, Magnolia Campus

12902 Usf Magnolia Dr

Tampa

FL

33612

USA

+18886633488

• Thoracic Surgery
• Cardiovascular Surgery

• Heart Disease
• Lung Cancer